Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Walenga

Showing results (131-140 of 196) with videos related to

Pageof 20
Sort By:
Thrombosis Research|April 15, 1987
Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challengesJ M Walenga, M Petitou, J C Lormeau, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 25, 2000
Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disordersH M Amin, S Ahmad, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1993
Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patientsP Bacher, B Horst, H G Breyer, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1995
Procoagulant and anticoagulant effects of intravascular contrast media as assessed by thromboelastographyO Iqbal, W Jeske, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Action of modified heparins on coagulation: in vitro and in vivo studiesA W Stemberger, A Riedl, S Haas, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1995
Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week periodB Lojewski, P Bacher, O Iqbal, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1991
Use of recombinant hirudin to increase the patency rate of microanastomosis in a rabbit modelT Hubbard, T Olivier, P Bacher, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1991
Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplastyJ Fareed, J M Walenga, F Leya, et al.
Investigative Radiology|February 1, 1995
Flow cytometric evaluation of platelet activation by ionic or nonionic contrast media and modulation by heparin and recombinant hirudinM J Koza, T C Shankey, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1985
Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragmentsJ Fareed, J M Walenga, K Williamson, et al.
Pageof 20

Showing results (131-140 of 196) with videos related to

Sort By:
Pageof 20
Thrombosis Research|April 15, 1987
Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challengesJ M Walenga, M Petitou, J C Lormeau, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|April 25, 2000
Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disordersH M Amin, S Ahmad, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1993
Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patientsP Bacher, B Horst, H G Breyer, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1995
Procoagulant and anticoagulant effects of intravascular contrast media as assessed by thromboelastographyO Iqbal, W Jeske, D Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1991
Action of modified heparins on coagulation: in vitro and in vivo studiesA W Stemberger, A Riedl, S Haas, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1995
Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week periodB Lojewski, P Bacher, O Iqbal, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|February 1, 1991
Use of recombinant hirudin to increase the patency rate of microanastomosis in a rabbit modelT Hubbard, T Olivier, P Bacher, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1991
Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplastyJ Fareed, J M Walenga, F Leya, et al.
Investigative Radiology|February 1, 1995
Flow cytometric evaluation of platelet activation by ionic or nonionic contrast media and modulation by heparin and recombinant hirudinM J Koza, T C Shankey, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1985
Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragmentsJ Fareed, J M Walenga, K Williamson, et al.
Pageof 20